Biogen (NASDAQ:BIIB – Get Free Report) issued its quarterly earnings results on Wednesday. , driven by 24% growth in the growth portfolio, which surpassed the legacy MS portfolio. Positive Sentiment: The growth portfolio is becoming a larger earnings driver. Growth Portfolio revenue increased 24% to $1.06 billion, surpassing revenue from the legacy multiple sclerosis portfolio. Reuters Biogen earnings articleGrowth Portfolio revenue increased 24% to $1.06 billion, surpassing revenue from the legacy multiple sclerosis portfolio.